JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB59715

Anti-Clostridium botulinum Toxin B antibody [GR-3G7]

Be the first to review this product! Submit a review

|

(0 Publication)

Mouse Monoclonal BXB antibody. Carrier free. Suitable for cELISA, Flow Cyt and reacts with Clostridium botulinum, Transfected cell line - Clostridium botulinum samples.

View Alternative Names

Botulinum neurotoxin type B, BoNT/B, Bontoxilysin-B, botB

1 Images
Flow Cytometry - Anti-Clostridium botulinum Toxin B antibody [GR-3G7] (AB59715)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-Clostridium botulinum Toxin B antibody [GR-3G7] (AB59715)

BOSC23 cells were transiently trans-fected with an expression vector encoding either Clostridium botulinum Toxin B (red curve) or an irrelevant protein (control transfectant). Binding of ab59715 was detected with a PE conjugated secondary antibody. A positive signal was obtained only with Clostridium botulinum Toxin B transfected cells.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

GR-3G7

Isotype

IgG1

Carrier free

Yes

Reacts with

Clostridium botulinum

Applications

cELISA, Flow Cyt

applications

Specificity

This antibody reacts with Clostridium botulinum Toxin B.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "cELISA" : {"fullname" : "Competitive ELISA", "shortname":"cELISA"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Clostridium botulinum": { "cELISA-species-checked": "guaranteed", "cELISA-species-dilution-info": "1/200 - 1/400", "cELISA-species-notes": "<p></p>", "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" }, "Transfected cell line - Clostridium botulinum": { "cELISA-species-checked": "notRecommended", "cELISA-species-dilution-info": "", "cELISA-species-notes": "", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1.2 µg for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/mouse-igg1-kappa-monoclonal-15-6e10a7-isotype-control-ab170190'>ab170190</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Storage buffer
pH: 7.2 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Clostridium botulinum toxin B often called "botulinum toxin B" or "botox B" is a neurotoxic protein produced by the bacterium Clostridium botulinum. This protein has a molecular mass of approximately 150 kDa. It is expressed during the bacterial life cycle and released into environments that promote anaerobic conditions. Mechanically botulinum toxin B interferes with acetylcholine release at the neuromuscular junction. The toxin binds to peripheral neurons enters the cells and cleaves specific proteins required for neurotransmitter exocytosis which results in muscle paralysis.
Biological function summary

The interruption of neurotransmitter release caused by Clostridium botulinum toxin B is essential for its paralytic effect. This action makes it part of a family of botulinum neurotoxins which all inhibit synaptic vesicle fusion through enzymatic cleavage of SNARE proteins. Though it generally acts independently it shares a similar mechanism with botulinum toxin type A another well-known neurotoxin. Through this action botulinum toxin B disrupts normal nervous system communication which can be significant in both clinical and research contexts.

Pathways

Botulinum toxin B is part of the cholinergic signaling pathway where it plays an important role in modulating neurotransmission. Its ability to cleave VAMP (vesicle-associated membrane protein) is important for its inhibitory action on synaptic vesicle fusion. This places it in a similar functional space as botulinum toxin A which targets SNAP-25 another SNARE protein. Both toxins effectively decrease acetylcholine release disrupting normal synaptic activity and muscle contraction processes.

Botulinum toxin B is associated primarily with botulism a serious illness characterized by muscle paralysis that can lead to respiratory failure. However in controlled medical settings it serves as a therapeutic agent in the treatment of dystonia a movement disorder causing muscle contractions and spasms. The therapeutic use relies heavily on its ability to reduce excessive muscle activity by targeting nerves similar to those affected in botulism which involves SNARE proteins like VAMP. This makes botulinum toxins including type A and B integral to understanding both the detrimental and beneficial effects of neuromodulation.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Botulinum neurotoxin type B. Botulinum toxin causes flaccid paralysis by inhibiting neurotransmitter (acetylcholine) release from the presynaptic membranes of nerve terminals of the eukaryotic host skeletal and autonomic nervous system, with frequent heart or respiratory failure. Precursor of botulinum neurotoxin B which has 2 coreceptors; complex polysialylated gangliosides found on neural tissue and specific membrane-anchored proteins found in synaptic vesicles (PubMed : 17167418, PubMed : 17167421, PubMed : 17185412, PubMed : 23807078). Receptor proteins are exposed on host presynaptic cell membrane during neurotransmitter release, when the toxin heavy chain (HC) binds to them (PubMed : 14504267). Upon synaptic vesicle recycling the toxin is taken up via the endocytic pathway (PubMed : 14504267). When the pH of the toxin-containing endosome drops a structural rearrangement occurs so that the N-terminus of the HC forms pores that allows the light chain (LC) to translocate into the cytosol (PubMed : 3856850). Once in the cytosol the disulfide bond linking the 2 subunits is reduced and LC cleaves its target protein on synaptic vesicles, preventing their fusion with the cytoplasmic membrane and thus neurotransmitter release. Binds to host peripheral neuronal presynaptic membranes via synaptotagmins 1 and 2 (SYT1 and SYT2) (PubMed : 14504267, PubMed : 8144634). Toxin binds to the membrane proximal extra-cytoplasmic region of host SYT1 and SYT2 that is transiently exposed outside of cells during exocytosis; exogenous gangliosides enhance binding and subsequent uptake of toxin into host cells (PubMed : 14504267, PubMed : 15123599). Toxin uptake into neural cells requires stimulation (incubation with K(+) to stimulate SYT protein receptor exposure); subsequently the toxin colocalizes with its receptor in host cells with a concomitant decrease in target protein (synaptobrevin-2/VAMP2) immunoreactivity (PubMed : 14504267). Toxin uptake can be blocked by the appropriate synaptotagmin protein fragments and gangliosides in cell culture and in mice (PubMed : 14504267, PubMed : 15123599). BoNT/B is a 'coincidence detector'; it requires simultaneous binding to coreceptor GT1b and low pH to transform into a membrane-bound, oligomeric channel (PubMed : 21925111, PubMed : 22720883). Whole toxin only has protease activity after reduction which releases LC (PubMed : 1331807, PubMed : 7803399).. Botulinum neurotoxin B light chain. Has proteolytic activity (PubMed : 1331807). After translocation into the eukaryotic host cytosol, inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2/VAMP2, blocking neurotransmitter release (PubMed : 1331807, PubMed : 7803399). In vitro the LC only has protease activity after reduction (PubMed : 1331807, PubMed : 7803399).. Botulinum neurotoxin B heavy chain. Responsible for host epithelial cell transcytosis, host nerve cell targeting and translocation of light chain (LC) into host cytosol. Composed of 3 subdomains; the translocation domain (TD), and N-terminus and C-terminus of the receptor-binding domain (RBD). The N-terminus of the TD wraps an extended belt around the perimeter of the LC; it does not seem to protect the active site, but might prevent premature LC dissociation from the translocation channel and protect toxin prior to translocation (PubMed : 10932256, PubMed : 17167418). Has 2 coreceptors; complex gangliosides found primarily on neural tissue and host synaptotagmin-1 and -2 (SYT1 and SYT2) which bind simultaneously to adjacent but separate sites at the tip of the HC (PubMed : 17167418, PubMed : 17167421, PubMed : 17185412, PubMed : 23807078, PubMed : 8144634). HC alone partially prevents uptake of whole toxin by neural cells, and delays paralysis onset by 160% (PubMed : 10413679). Binding probably positions the TD for integration into the synaptic vesicle membrane (PubMed : 17167418, PubMed : 23807078). The HC forms channels at low pH that mediate transport of the light chain (LC) from the endocytic vesicle to the cytosol (PubMed : 3856850). Binds gangliosides GD1b and GT1b (PubMed : 10413679, PubMed : 14731268). Gangliosides are not only a coreceptor, but also required for uptake into nerve cells (PubMed : 17167418, PubMed : 21925111). HC alone binds to host receptor proteins SYT1 and SYT2 (PubMed : 14504267, PubMed : 15123599, PubMed : 17185412, PubMed : 19650874). Interaction with SYT1 protein does not require SYT1 glycosylation (PubMed : 19476346). The HC C-terminus (approximately residues 1079-1291) interacts with host SYT2 (PubMed : 15123599, PubMed : 17167418, PubMed : 17167421, PubMed : 23807078). Has higher affinity for SYT2 than SYT1 (PubMed : 17167421, PubMed : 17185412). Significantly decreases uptake and toxicity of whole BoNT/B and BoNT/G (PubMed : 19650874).
See full target information botB

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com